Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Tanimilast and Itraconazole in Healthy Subjects
NCT04739774Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Feb 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tanimilast in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the last measurable concentration. Started Feb 2021; status: completed.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04739774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739774.